Grant
Affectis Pharmaceuticals has announced that it has been awarded a €550,000 grant from the Bavarian Technology Promotion Programme (BayTP) of the Bavarian Ministry of Economics, to fund the identification and characterisation of drugs for the treatment of major depression.
Herbert Stadler, CEO and co-founder of Affectis, said, “We are pleased to have received this highly competitive grant from BayTP. The funds will accelerate the development of three innovative drug candidates that aim to address the needs of patients suffering fromdepression.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
